Intermittent androgen deprivation (IAD) seems to be as effective as continuous androgen deprivation (CAD), and may offer advantages with respect to sexual potency.
This conclusion is based on a review of data from 19 phase 2 and eight phase 3 clinical trials of IAD for prostate cancer treatment reported over a recent 10-year period. Sexual dysfunction, hot flushes, and fatigue are well-known adverse effects of androgen deprivation.
IAD allows for hormonal recovery by alternating androgen blockade with treatment cessation. The literature review, detailed in European Urology (2010;57:49-59), indicated that IAD was comparable to CAD in terms of biochemical progression, progression-free survival, and overall survival.
In addition, IAD demonstrated tolerability benefits, particularly in terms of sexual function.